For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

CTSU S1931

Trial Overview

Official Title

Comparing The Outcome Of Immunotherapy-Based Drug Combination Therapy With Or Without Surgery To Remove The Kidney In Metastatic Kidney Cancer

Study Purpose

To compare Standard Systemic Therapy alone to Standard Systemic Therapy plus surgery to remove all or part of the kidney with tumor.

Diagnosis

Patients who have kidney cancer that has spread outside of their kidney.

Eligibility

Participants must have a histologically proven diagnosis of clear cell or non-clear cell renal cell carcinoma.

Participants with collecting duct carcinoma histology are not eligible.

Participants with multifocal or bilateral tumors are eligible

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

This study has 2 study groups:

  • Group 1: Patients in this group will continue to receive standard systemic therapy until their disease gets worse or the side effects are too great.
  • Group 2: Patients in this group will continue to receive standard systemic therapy, but patients will also have surgery to remove part or all of your kidney.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
S1931